Pharmafile Logo

Living with NASH: An Unexpected Diagnosis

Published in eyeforpharma November 2017 by Mariel Metcalfe

With no current licensed treatments and more than 20 compounds in phase II and III, the liver disease non-alcoholic steatohepatitis (NASH) represents a huge opportunity for pharma companies – if they understand patient needs.

As our waistlines thicken and our activity levels decrease, another chronic illness threatens to disturb our comfortable lifestyles. And, because it’s relatively unknown, diagnosis comes as a shock to patients, who usually associate liver disease with heavy consumption of alcohol…

Read the full article: https://www.researchpartnership.com/news/2017/11/living-with-nash-an-unexpected-diagnosis/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Cool heads in a crisis?

Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics

Biosimilars: Bringing patients into the conversation

Published in eyeforpharma January 2017 by Mariel Metcalfe

Access and elimination: the future of DAAs in hepatitis C

Published in Pharmaphorum January 2017

EphMRA One Day Meeting

We are delighted to be attending and presenting a paper at the EphMRA one day meeting on Tuesday 21st February, in London

Video: Segmentation research

Why would a pharma company want to carry out a segmentation study? What are some of the challenges? Head of Business Analytics Tom Nolte and Associate Director Dr Marianne Jaeger...

Pharmaceutical Market Research Conference 2017

We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 1-2 February in Parsippany, NJ.

Shifting perceptions of the use of probiotics in IBS Management

Our client was planning to launch an over-the-counter (OTC) probiotics product for the purposes of improving IBS management and wanted to understand current perceptions, practices and usage amoungst a range...

Nutraceuticals in India: A Challenging Opportunity

Published in eyeforpharma December 2016 by Marc Yates

Research Partnership makes annual donation to Forever Projects

Research Partnership has made a seasonal donation of US$5,000 to our chosen charity, Forever Projects

A Bitter Pill?

The ideal route of admin isn’t clear cut in the global marketplace